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REVIEW
Abstract: Cancer pain is often suboptimally managed. The underestimation and
undertreatment continues to be a problem despite the availability of consensus-based guidelines.
Most patients with cancer develop pain. The prevalence and severity of pain among cancer
patients varies according to primary and metastatic sites and stage of disease. Opioid therapy
is the cornerstone of management of severe chronic pain in the field of cancer patients and in
general in palliative care medicine. Since this class of drugs is the cornerstone of the treatment,
optimizing its use may be useful in clinical practice. For this purpose we focused on 4 distinct
issues: 1) How to implement the use the opioids in cancer patients; 2) How to optimise the
use of morphine in cancer patients; 3) The management of side effects and opioid switching;
4) What is the role of other potent opioids. A holistic approach including an appropriate use
of opioids may improve pain control in most cancer patients, particularly for those with
advanced disease.
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Introduction
Most patients with cancer develop pain. The prevalence and severity of pain among
cancer patients varies according to primary and metastatic sites and stage of disease.
At least 30% of cancer patients receiving active treatment for metastatic disease
have significant cancer-related pain, while this percentage increases to between 60%
and 90% in those with advanced disease (Levy and Samuel 2005).
Opioid therapy is the cornerstone of management of severe chronic pain in the
field of cancer patients and in general in palliative care medicine (Hanks et al 2001;
Davis et al 2005).
Cancer pain is often suboptimally
 managed. The underestimation and
undertreatment continues
 to be a problem despite the availability of consensus-based
guidelines.
Healthcare professionals may be overly concerned
 about the development of
analgesic tolerance, side-effect
 management, and regulatory concerns. They may not
be aware of current knowledge concerning the mechanisms of pain and the modalities
available for its
 control. Similarly, patients may be concerned about
 side effects,
tolerance and the untrue thought that in patients with cancer pain is an inevitable
symptom (Davis et al 2005).
Current pain treatment is based on the World Health Organization (WHO) three-
step analgesic ladder. The WHO ladder has been extensively validated (Hanks et al
2001). It involves a stepwise approach to the use of analgesic drugs. The philosophy
behind the WHO ladder is to give framework principles, which allows flexibility in
the choice of analgesics. Potent opioids are the analgesics of choice as the third step
of the WHO guideline. Opioids should be given “by the mouth, by the clock, by the
ladder”. Since this class of drugs is the cornerstone of the treatment, optimizing its
use may be useful in clinical practice.
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For this purpose we focused on 4 distinct issues: 1) How
to implement the use the opioids in cancer patients; 2) How
to optimize the use of morphine in cancer patients; 3) The
management of side effects and opioid switching; 4) What
is the role of other potent opioids?
How to implement the use the
opioids in cancer patients
There are at two issues, which should be considered:
1) All patients should receive an appropriate assessment,
including screening for the presence of pain, and when
it is present it is necessary a comprehensive evaluation.
Pain assessment should include the “intensity” of pain,
“how” and “when” it manifests and disappears, the
location and quality of pain, and aggravating and
alleviating factors. It is crucial to evaluate previous
treatments and their effectiveness. It is important to
establish the impact of pain on physical and emotional
function. This approach needs an interdisciplinary,
collaborative care planning. The interdisciplinary team
should bring together individuals with a diversity of
training, who share the goal of  “an holistic pain control”.
The members of the team should include the physicians,
nurses, social workers, physiotherapist, occupational
therapists, dietician, pharmacist, volunteer, and in
particular situations, the chaplain, the music and the art
therapist (Gordon et al 2005). Most importantly, patients
and family should be involved to improve compliance
and provide information about available pain control
options. It is important to tailor treatments and identify
the needs and desires of our patients. Trowbridge and
colleagues (1997) found that standardized pain
assessment alone improved
 cancer pain management and
reduced patient-reported pain severity.
2) Further improvement in symptom management might
be achieved with simple protocols or guidelines for
symptom management. For example, Du Pen and
colleagues (1999) found that the institutional use of a
simple protocol for cancer pain management reduced
pain severity. Similarly Cleeland and colleagues (2005)
suggested that a protocol for cancer pain management
can improve pain control.
How to optimize the use of
morphine in cancer patients
Morphine is a cornerstone for the management of pain in
cancer patients (Hanks et al 2001). There is no proven
superiority of morphine as compared with other available
opioids. However morphine is the most used opioid and
this is due to extensive experience among physicians, a large
variety of formulations and no clinically relevant ceiling
effect to analgesia. Morphine is also the most cost-effective
analgesic. However morphine has some limitation. The
systemic availability of morphine by the oral route is poor
and this may cause a great inter-individual variability in
doses appropriate for an adequate response. In addition
active metabolites may contribute to toxicity, especially for
patients with renal impairment.
The oral route is the simplest and of choice for
administering morphine. The dose of morphine should be
titrated with a normal release formulation given every 4
hours. The titration with normal morphine helps to rapidly
achieve the steady state. In addition this strategy helps to
adjust promptly the dose during the dose finding period. If
the pain is not controlled during the dose titration, a
gradually increase of the dose by 50% may be
recommended: for example patients who begin with 10 mg
may receive first 15 mg and then 20 mg until an active dose
is reached. The starting dose depends by previous treatments:
patients coming from step two will start with 10 mg of
normal morphine preparation every 4 hours; on the contrary
if the step two is omitted, 5 mg of normal morphine
preparation every 4 hours may be an adequate dose for the
beginning of titration. During the titration period morphine
should be given every 4 hours and a full 4-hourly dose should
be used for rescue. Consequently the rescue dose should be
increase at the same time and to the same level in line with
the regular four hourly dose. In the general practice once
the patient’s pain has been controlled and a stable dose is
achieved for 48 hours, the regular dose may be converted
to an oral controlled-release (CR) preparation. In several
controlled clinical trials, investigating the management of
pain in cancer patients, CR morphine given every 12 hours
provided effective analgesia with a discontinuation rate of
only 2%. From a practical point of view, it is important to
provide an immediate release (IR) morphine preparation to
patients stabilized on CR morphine to be used “as required”
for incidental pain. For patients who are unable to take oral
morphine, the preferred alternative route to administer
morphine is the subcutaneous way. The peak concentrations
are achieved within 15–30 minutes, and the onset of action
is more rapid than that achieved with the oral formulation.
Subcutaneous morphine does not undergo first pass
metabolism. To convert a 24 hour dose of oral morphine to
an equivalent subcutaneous, the dose of oral morphineTherapeutics and Clinical Risk Management 2006:2(4) 449
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should be divided by three to achieve an equianalgesic effect
due to the patency ratio of nearly 1:3. For example, 90 mg
of oral sustained morphine release twice daily is equivalent
to 60 mg subcutaneous morphine. In patients with
breakthrough pain, subcutaneous morphine injection
equivalent to a 4 hourly morphine dose should be
considered.
The role of intravenous morphine is more limited than
the oral or subcutaneous infusion. Intravenous morphine
may be considered for patients with a central venous access,
generalized oedema, or with complications due to local
intradermal infusion (Hanks et al 2001).
Finally there is controversy about the role of spinal
morphine administration. Smith and colleagues (2005)
suggested that spinal opioids may sustain pain control, less
drug-related toxicity, and possibly better survival (Smith et
al 2002, 2005). However the above mentioned studies have
important limitations (Davis et al 2003; Ripamonti and
Brunelli 2003) In addition three studies investigated the early
use of such type of administration, all of which found no
advantage (Vainio and Tigerstedt 1988; Sjogren and Banning
1989; Kalso et al 1996). The European Association for
Palliative Care (EAPC) stated that few patients need spinal
opioids (Hanks et al 2001). This type of administration
should be considered in the niche of patients who received
pain control with intolerable side effects, or when pain
control has been unsatisfactory with opioid rotation. If
patients receive adequate opioids early, only a small subset
will need spinal opioids.
The management of side effects
Morphine is generally well tolerated, it has been estimated
that 10%–30% of patients treated with
 oral morphine do
not have a successful outcome
 because of excessive adverse
effects or inadequate analgesia (Cherny et al 2001).
The management of adverse effects remains a major
clinical challenge, especially because the lack of studies
comparing
 various therapeutic approaches able to counteract
the side effects. The first step in the evaluation of patients
is to differentiate the adverse effects from other causes such
as hystopathology of the tumor, sites of the disease,
concomitant medication and comorbidity, which may mimic
opioid-induced adverse effects. Patients with cerebral or
leptomeningeal metastases, dehydration, hypercalcemia,
hyponatriemia, renal or liver failure may have drowsiness
and cognitive impairment. Similarly concomitant
chemotherapy or radiotherapy, or both, which can cause
bowel obstruction, may mimic opioid-induced nausea or
vomiting.
If external factors, which may mimic opioid-induced
adverse events, are reasonably excluded, physicians should
consider several approaches to the management of opioid
adverse effects: 1) a reduction of opioid dose; 2) the
symptomatic management of the opioid toxicity; 3) opioid
rotation, also defined as opioid switching; 4) switching the
route of administration.
It may be difficult to reduce the dose of opioids for
patients with a well controlled pain, because of the loss of
pain control. In these cases, several strategies may be
applied: administration of non-opioid coanalgesic; the
addition of adjuvant analgesic; administration of appropriate
palliative chemotherapy, radiotherapy or surgery. These
approaches have several limitations and should be tailored
to the single patient. It is known that non-steroidal anti-
inflammatory agents may cause additive toxicities in patients
treated with opioids. Cancer patients receiving
chemotherapy such as cisplatin may be at risk of developing
renal toxicity. This risk may be increased by the concomitant
use of nonsteroidal anti-inflammatory drugs (NSAIDs).
They may provide additive pain relief for some patients who
already are receiving opioids for moderate to severe cancer
pain. According to a recent Cochrane review, most studies
reporting safety data of opioids in combination with NSAIDs
are small and heterogeneous in terms of type of cancer or
cancer pain, level of pain among participants, and specific
medications used. In addition, none of the studies lasted
more than two weeks, so potential adverse effects from
prolonged use of these treatments individually or in
combination could not be assessed or compared (McNicol
et al 2005.).
Furthermore, patients with neuropathic pain drugs such
as gabapentin may cause drowsiness and cognitive
impairment in the titration phase, with may be additive to
opioids. Chemotherapy and radiotherapy may increase
nausea, vomiting, or cognitive impairment. Finally
pharmacokinetic interaction between opioids and
chemotherapic agents may increase the toxicity of opioids.
Gastrointestinal side effects
Nausea and vomiting are common during the titration phase,
tolerance over time, so subsequently may disappear without
therapy (Walsh et al 1992; Cherny et al 2001). Several agents
have been suggested for patients with persistent nausea and
vomiting: metoclopramide, 5-HT3 antagonists, haloperidol,Therapeutics and Clinical Risk Management 2006:2(4) 450
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corticosteroids, or phenothiazine. There is not evidence
suggesting the superiority of one antiemetic over another.
On variance, constipation shows no tolerance over time.
This type of side effect has been reported in 40% to 70% of
patients receiving morphine for chronic pain. Several agents
have been suggested to counteract this side effect: senna,
bisacodyl, phenolphthalein, and lactulose. As for nausea and
vomiting there is no evidence to suggest the superiority of
one laxative over another.
Central nervous system side effects
As for some gastrointestinal side effects like nausea and
vomiting, a transient cognitive impairment is common after
the initiation of opioid therapy. Sedation, the most commonly
seen symptom of toxicity, is considered the “tip of the
iceberg” leading toward delirium and obtundation (Bruera
et al 1989, 1992). When sedation occurs, other causes need
to be excluded, and one can wait 7 to 10 days to allow
tolerance to develop. One should also discontinue other
sedating adjuvant medications. If symptoms persist, the next
step is opioid dose reduction or opioid rotation to an alternate
drug or another route of administration. When evaluating
the patient with delirium, it is important to consider non-
opioid causes, including infection, electrolyte imbalance,
and other potentially neurotoxic medications commonly
used as adjuvants, such as the antidepressants and
anticonvulsants. It is prudent to discontinue all
benzodiazepines, and consider a trial of hydration. Opioid-
induced myoclonus is often a sign of evolving delirium.
Risk factors include dehydration and other medications, such
as selective serotonin reuptake inhibitors, dopamine
antagonists, and NSAIDs. These drugs (NSAIDs) are
thought to produce mild renal insufficiency and decrease
opioid and metabolite excretion. Treatments to consider are
hydration, opioid rotation, and GABA agonists such as
clonazepam and baclofen.
For severe opioids-induced cognitive impairment, for
example delirium, neuroleptics, specifically haloperidol, are
the most recommended drugs. For patients with delirium
and severe agitation, a treatment with neuroleptics such as
co-administered haloperidol and benzodiazepine is
suggested (Battaglia et al 1997). An improvement of agitated
confusion even after opioid rotation was reported in the
literature (Paix et al 1995; Ashby et al 1999).
Patients with severe agitation are often co-administered
a benzodiazepine (Battaglia et al 1997). This latter class of
drugs have been recommended for myoclonus. Several
reports have reported a role for diazepam, clonazepam,
midazolam, and baclofen (De Conno et al 1991; Eisele et al
1992; Obeso 1995). Unfortunately there are no prospective
trials on the treatment of opioid-induced myoclonus.
Opioid switching to improve pain
relief and drug tolerability
There are several clinical experiences suggesting that a
failure to respond to one opioid does not mean failure to
respond to all opioids (Mercadante 1999). Although there
are different biological explanations behind this
consideration, the true reason why opioid substitution is
successful remains unclear. Pharmakogenetic,
pharmakogenomic, pain mechanism, and degree of cross
tolerance should be considered, but it is reasonable to think
that perhaps there is no single specific explanation. Every
user of opioids is aware that poorly responsive pain may
arise because of the development of analgesic tolerance,
while no tolerance to adverse effects develops to the same
extent. This means that the escalating dose of any opioid
may reach a level at which there is a detrimental balance
between analgesia and side effects.
The term opioid rotation has been reported in literature.
This implies that there is a rotation back to the original opioid
after switching. As very few reports reported a true opioid
rotation, the term opioid switching may be more appropriate
in clinical setting, because it reflects more strictly the clinical
study results. Different strategies have been reported,
including switching from oral or subcutaneous morphine
to methadone, fentanyl to methadone, and morphine to
oxicontin. As regards the switching from morphine to
methadone, a previous report by Ripamonti and colleagues
(1998) showed a dose ratio of 1:4 (1 mg of oral methadone
= 4 mg of oral morphine) for patients receiving less than
90 mg of morphine, while a ratio of 1:8 and 1:12 has been
suggested for those patients receiving 90 mg/day to 300 mg/
day and greater than 300 mg/day respectively (Ripamonti
et al 1998). However in patients with uncontrolled pain, a
starting dose of methadone increased by approximately
20%–30% has been suggested (Mercadante et al 2001). It
is reasonable to think that future studies are needed in order
to better define the dose ratio between morphine and
methadone.
Recently Riley and colleagues (2006) reported a
prospective, observational, controlled clinical study
evaluating 186 patients with poor pain control or with
morphine side effect, switched to oxicodone as first line.
Among 48 switchers, 41 patients (87%) did improve when
switched to an alternative opioid. It is remarkable that 37 ofTherapeutics and Clinical Risk Management 2006:2(4) 451
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41 patients were switched to oxycodone. In a multivariate
analysis the authors reported a clinical model for switching
from morphine to an alternative opioid. In this study the
need to switch was dependant on white cell count, weight,
concomitant use of 5HT3 antiemetics, beta blockers, proton
inhibitors, tumor diagnosis of the lower gastrointestinal tract
and recent chemotherapy. These data seem so important
because we strongly need a clinical objective model for
predicting switchers.
Recently the Cochrane collaboration reported a review
investigating the usefulness of opioid switching for patients
with pain (Quigley 2006). The conclusion of this critical
review is that there is no robust evidence base for the practice
of opioid switching. However among investigated trials 13
of the 14 prospective studies reported that switching of
opioids improved pain control, reduced opioid adverse effect
or both. This means that switching opioids may be the only
effective option for a subgroup of cancer patients despite
the lack of evidence base for this strategy to counteract the
imbalance between pain control and side effects. In a
dedicated center for pain management, switching may be
an elegant strategy for pain control. This approach needs
familiarity with a range of opioids and with the use of opioid
dose conversion tables previously published by the EAPC
(Hanks et al 2001). The use of tables may represent a valid
therapeutic option only in centers with experience in
palliative care. One caveat with opioid conversion tables is
that they are usually based on single doses of drugs or drugs
at steady state and may not accurately represent the dose
needed when titrating uncontrolled pain. The table of the
relative potencies of opiates have been reasonably well
established in naive patients and are not accurate in tolerant
patients and using these relative potencies when switching
drugs in patients highly tolerant can lead to serious problems.
Clinically, it is often necessary to reduce the equivalent dose
calculated from the relative potency ratios in naïve patients
of the second drug by 50% or more (Pasternak 2005).
Several authors recommend decreasing the
“equianalgesic” dose by 25% to 50% when switching to a
new opioid to account for incomplete cross-tolerance
(Ripamonti et al 1998).
What is the role of other potent
opioids
Oral morphine has been recognized as the analgesic of
choice in the management of cancer patients even though it
is not based on proven therapeutic superiority over other
options. In addition a number of patients cannot tolerate it
at the doses necessary to achieve an adequate analgesia
without experiencing adverse effects.
Patients who don’t achieve adequate pain relief or
experiencing side effects with morphine may often be
successfully treated with other potent opioids. Among those,
methadone, long acting oxycodone, and transdermal fentanyl
have been extensively studied in controlled clinical trials.
Methadone
Methadone is a µ-opioid agonist, approved for oral and
intramuscular use, it also is used rectally, intravenously,
subcutaneously, epidurally, and intrathecally. Methadone is
a highly lipophilic molecule that is suitable for a variety of
administration routes. Oral methadone has a bioavailability
close to 80% compared with 20%–30% for morphine.
Analgesia and typical opioid side effects are the result of
action at the µ-opioid receptor. The elimination half life is
of about 22 hours. Because of its long half-life, plasma levels
of methadone may take five to seven days to stabilize.
Several days are required to reach steady-state plasma
levels, so monitoring should continue after the last dosage
increase to detect potential overdose. Toxicity occurs more
frequently in patients previously exposed to high dosages
of opioids. Transition from high-dosage opioids may be
difficult and needs assistance from a pain specialist.
Methadone has a number of potential advantages
compared with
 other opioids, including morphine. Due to
the low cost it could be a good choice of an opioid
 for first-
line cancer pain treatment for low-income populations
 or in
developing countries. In addition, methadone does not
 have
any known active metabolites and does not undergo
significant
 renal elimination (Bruera and Sweeny 2002).
Unlike morphine, it usually is not necessary to adjust the
dosage of methadone in patients with renal insufficiency.
Another potential advantage of methadone
 over other
opioids is that this drug is a relatively potent N-methyl-D-
aspartate (NMDA) receptor antagonist.
 NMDA has been
implicated in
 the development of neuropathic pain and
opioid tolerance (Elliot et al 1994). One disadvantage of
using methadone is that it has a long and
 unpredictable half-
life, which can makes titration difficult
 to achieve
(Ripamonti et al 1997, 1998). Titration might be easier and
safer in
 patients who have not previously received strong
opioids (Mercadante et al 1998).
The results of a recent randomized clinical trial did not
support a relatively more
 effective role for methadone in
patients with neuropathic pain
 syndromes as compared with
morphine (Bruera et al 2004). Up now there is no trialTherapeutics and Clinical Risk Management 2006:2(4) 452
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evidence to support the proposal that methadone has a
particular role in neuropathic pain of malignant origin.
Methadone has a similar efficacy and a comparable side
effect profile with morphine. Due to complex
pharmacokinetics, its use requires expertise and experienced
doctors.
Oxycodone
Oxycodone is a µ-opioid receptor specific ligand with clear
agonist properties, with a high oral to parenteral
bioavailability, and a two-fold greater oral potency than oral
morphine. Oxycodone has a more favorable
pharmacokinetic profile. Its oral bioavailability is
significantly higher and therefore the interindividual
variation in bioavailability and expected plasma
concentrations is less. CR oxycodone every 12 hours is as
effective as IR oxycodone four times daily in managing
moderate to severe cancer-related pain and was associated
with fewer reports of adverse events (Kaplan et al 1998)
Maddocks and colleagues (1996) showed that
oxycodone administered by the subcutaneous route can
provide effective analgesia without significant side effects
in patients with morphine-induced delirium. Two
prospective studies confirmed the data (Heiskanen and Kalso
1997; Mucci-LoRusso et al 1998). Less nausea (Heiskanen
and Kalso 1997) and less pruritus (Mucci-LoRusso et al
1998) have been reported with oxycodone compared with
morphine.
Both CR oxycodone and CR morphine provide, at proper
doses, pain relief for 12 hours. The onset of analgesia is
faster with CR oxycodone (Curtis et al 1999). Three
randomized and controlled studies have compared CR
oxycodone and morphine. Two of these studies have used
crossover designs (Heiskanen and Kalso 1997; Bruera et al
1998) whereas one has been a parallel group study (Mucci-
LoRusso et al 1998). A total of 177 patients were included
in these studies and 73% completed the study protocol. In
the trial by Bruera and colleagues (1998), the median
oxycodone/morphine dose ratio was 1:5 and the maximum
was 2:3. These studies showed that oxycodone and morphine
are equally efficacious. Oxycodone may be an interesting
drug for pain control as first line therapy but also in the
switching strategy when morphine is used as drug of choice.
CR oxycodone can be used as readily as the IR formulation
for titration to stable analgesia in patients with moderate to
severe chronic pain due to cancer. CR oxycodone is
characterized by an initial rapid absorption of 38% of the
dose (t 1/2 after absorption [abs] =37 minutes), providing
onset of analgesia within 1 hour in most patients (Mandema
et al 1996; Salzman et al 1999).
Transdermal fentanyl
Fentanyl is a lipid soluble synthetic opioid. The high lipid
solubility facilitate the absorption though the skin. The
transdermal delivery system provides a consistent rate of
fentanyl to the microcirculation of the skin and the steady
state rate is achieved at 72 hours. This type of delivery is
applied every 3 days. Transdermal fentanyl was compared
with CR morphine in patients with terminal cancer pain
(Ahmedzai and Brooks 1997). No significant differences
in analgesic efficacy or adverse events were observed
between the two groups of patients. Due to limitations of
patch size small increment of dose are not possible. In
addition the long half life does not allow rapid change of
dose for patients with unstable pain.
Recently Ripamonti and colleagues (2006) showed that,
in Italy, there is a trend to use fentanyl patch as first-choice
strong opioid in cancer patients in situations such as titration
phase, in the presence of unstable pain, and in the absence
of dysphagia or gastrointestinal symptoms where the use of
oral morphine is not contraindicated. According to the EAPC
(Hanks et al 2001) transdermal fentanyl is reserved for
patients who require stable opioid doses or for patients
unable to take oral morphine as an alternative to the
subcutaneous route.
Conclusions
Cancer pain is often suboptimally  managed. The
underestimation and undertreatment of cancer pain
continues
 to be a problem despite the availability of
consensus-based guidelines. A holistic approach including
an appropriate use of opioids may improve pain control in
most cancer patients, particularly for those with advanced
disease.
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